Insiders, People, R&D

Exclusive: At Hal Barron’s R&D group at GSK, consensus is out, leaders are in and watch out for an ‘intense drive’ to spur the late-stage pipeline

Image: Axel Hoos, Hal Barron, John Lepore, Kevin Sin and Tony Wood John Carroll, Endpoints News

Hal Barron is talking offense. He’s talking teams and leaders. And 9 months into the job of a lifetime running a global, multibillion-dollar R&D shop, he’s got his game plan worked out and his top crew lined up.

Almost literally, it turned out, which I’ll get to later.

“I’m going to empower people,” Barron tells me emphatically, “and they’re going to make important decisions."

“I feel a sense of urgency,” he says later, returning to a theme in our conversation.

We’re in a conference room on the top floor of an unmarked, mid-19th century Georgian townhouse that’s been refitted as a small operations center just off Berkeley Square in the center of London. Barron, who’s based in the Bay Area, has taken command of it for a few days, summoning members of the inner circle, with roots in San Francisco, the UK and Philadelphia.

I too was summoned, in a way.

Endpoints Insider

Endpoints Enterprise

Unlock this article along with other benefits by subscribing to one of our paid plans.
Already a subscriber? Log in now
← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,400+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->